Suppr超能文献

渗透性疗法治疗脑水肿临床应用的演变

The Evolution of the Clinical Use of Osmotic Therapy in the Treatment of Cerebral Edema.

作者信息

Diringer Michael N

机构信息

Neurocritical Care Division, Department of Neurology, Washington University, Campus Box 8111, 660 S Euclid Ave, St Louis, MO, 63110, USA.

出版信息

Acta Neurochir Suppl. 2016;121:3-6. doi: 10.1007/978-3-319-18497-5_1.

Abstract

For almost a century, it has been known that hypertonic solutions shrink cerebral tissue. Early attempts used hypertonic solutions of ions (sodium, magnesium) and sugars (glucose, dextrose, sucrose), concentrated albumin, and, later, urea. These early attempts were largely abandoned because the effect was short lived and often followed by a period of rebound edema. This was a result, to a great extent, of the osmotic agent either being metabolized or crossing the cell membrane.Renewed interest in osmotic therapy came in the 1960s, with the introduction of intracranial pressure monitoring in head injury and the use of mannitol as an osmotic agent. In the 1990s, use of hypertonic saline was reintroduced as an alternative to address concerns about mannitol. More recently, administration of hypertonic saline has transitioned from boluses to continuous infusions. The rationale for and data supporting the use of continuous infusions are presented.

摘要

近一个世纪以来,人们已经知道高渗溶液会使脑组织收缩。早期尝试使用离子(钠、镁)和糖类(葡萄糖、右旋糖、蔗糖)的高渗溶液、浓缩白蛋白,以及后来的尿素。这些早期尝试大多被放弃了,因为效果是短暂的,而且往往随后会出现一段时间的反弹性水肿。这在很大程度上是由于渗透剂要么被代谢,要么穿过细胞膜。随着20世纪60年代颅内压监测在头部损伤中的引入以及甘露醇作为渗透剂的使用,人们对渗透疗法重新产生了兴趣。在20世纪90年代,高渗盐水作为解决对甘露醇担忧的替代方法被重新引入。最近,高渗盐水的给药方式已从推注转变为持续输注。本文介绍了持续输注的理论依据和支持其使用的数据。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验